Related Experiment Video
Updated: Jun 8, 2026

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
Published on: September 11, 2012
Chronic Triclosan Exposure Promotes Metabolic Dysregulation and Colitis in Mice: A Dose-Dependent Relationship
Guo Lian1, Songyi Chen1, Jing Chen1
1Ministry of Education Key Laboratory of Analytical Science for Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China.
Abstract:
Triclosan (TCS), a widely used antimicrobial agent in personal care products, typically undergoes phase II metabolism for detoxification. Notably, its phase II metabolites can be reconverted into the parent TCS by microbial activity, revealing their potential toxicological risks. Hence, this study investigated the tissue distribution and metabolic effects in mice following 160 day exposure to TCS at 0.5 or 5 mg/kg/day. The results showed that TCS mainly accumulated in the colon, where it disrupted energy metabolism, enhanced purine metabolism, and elevated reactive oxygen species levels. Lipidomic analyses revealed dose-dependent perturbations: the low dose promoted sphingomyelin synthesis, while the high dose stimulated glycerophospholipid synthesis. Mechanistic evidence from molecular docking and Western blot suggested that these effects might be linked to TCS-induced alterations in mitofusin 2 activity. Overall, these findings provide new insights into the dose-specific mechanisms of TCS-induced intestinal toxicity.
More Related Videos
11:04The Citrobacter rodentium Mouse Model: Studying Pathogen and Host Contributions to Infectious Colitis
Published on: February 19, 2013
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
Dysbiosis of the Gut Microbiota
Microbiota Modulation by Antibiotics
Inflammatory Bowel Disease III: Crohn's Disease